Next few monthsThe way I figure, Q4 will report record annual revenues but the results will likely be ugly since they have probably filled some Q4 contractual obligations at a gross margin loss, like done and indicated in Q3. Nothing pretty there.
Then Q1 will likley include the tail-end business operations and flushing of Global discontinued operations through the balance sheet. Never anything pretty in writing off a major purchase from a couple of years ago.
Q2 may finally start giving us clues as to our "new normal", which relatively speaking I can't see being too far ahead from pre-BioCloud and pre-Global which contributed $10s of millions in revenues. We will have additional share dilution as a result of all the financings. There is also something that does not show up on financials and difficult to put a valuation on: I think many will agree that there is a significant loss of credibility. Progress made in other business versus these negatives, not sure what the net result is, but in my mind the starting point is worse than before the BioCloud hype and Global expansion. KNR becomes one of countless other micro-caps that can be made to sound good - I'd rather gamble on cyrptos at this point.
In summary, I think we have to wait for another half year to get a glimpse of what KNR looks like today because quarterly financial reporting is a couple of months behind or almost half a year from month 1 of a quarter.
One kind word to sum up the last few KNR years: unbelievable!